Grob P J, Binswanger U, Blumberg A, Gloor H J, Hany A, Herwig W, Iselin H, Zàruba K, Bolla K
Surv Immunol Res. 1985;4 Suppl 1:107-15.
The influence of adjuvant thymopentin therapy on the effect of vaccination with HB-Vax was investigated in three independent double-blind studies in which three different time/dose schedules of the adjuvant therapy were used. The first study was conducted with 30 hemodialyzed patients who had previously been non- or hyporesponders. Forty and 26 nonvaccinated hemodialyzed patients were chosen for the two additional studies. A 50-mg dose of thymopentin or placebo was administered subcutaneously in all studies. In one study, in which only one adjuvant injection was administered simultaneously with each vaccine injection, thymopentin inhibited the antibody response. On the contrary, in the other two studies, in which three injections of adjuvant were administered during the week following the vaccination (in one of these studies three injections were also given before the vaccination), no difference in the effect of vaccination was observed in patients on either placebo or thymopentin. Comparison of the results of the present studies with those of earlier observations emphasizes the importance of time/dose schedules of adjuvant therapy in vaccination.
在三项独立的双盲研究中，研究了辅助性胸腺五肽疗法对HB-Vax疫苗接种效果的影响，其中使用了三种不同的辅助治疗时间/剂量方案。第一项研究针对30名先前无反应或反应低下的血液透析患者进行。另外两项研究选择了40名和26名未接种疫苗的血液透析患者。在所有研究中，均皮下注射50毫克剂量的胸腺五肽或安慰剂。在一项研究中，每次疫苗注射时仅同时进行一次辅助注射，胸腺五肽抑制了抗体反应。相反，在另外两项研究中，在接种疫苗后的一周内进行了三次辅助注射（在其中一项研究中，在接种疫苗前也进行了三次注射），接受安慰剂或胸腺五肽治疗的患者在疫苗接种效果上未观察到差异。将本研究结果与早期观察结果进行比较，强调了辅助治疗时间/剂量方案在疫苗接种中的重要性。
